Guido Lancman, MD, on the Use of IVIg in Patients with Multiple Myeloma Receiving Daratumumab
Guido Lancman, MD, sought to evaluate the effect of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab.
Research presented at the 2020 American Society of Hematology Annual Meeting & Exposition sought to evaluate the effect of intravenous immunoglobulin (IVIg) on infections in patients with multiple myeloma receiving daratumumab (Darzalex).
Infection risk in multiple myeloma is the result of a complex interplay of disease, treatment, and age-related risks and co-morbidities.
In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, discussed the results of the study.
Transcription:
What we found was that in the periods [where] patients were getting IVIg, the rate of infections overall actually decreased by 39% from 1.96 [infections] per patient year to 1.21 per patient year. And when we looked at grade 3 or higher infections, we actually found an even greater reduction of 72% from 0.71 to 0.2 infections per patient year.
